Beyond Air (XAIR)
NASDAQ:XAIR
Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$0.54
-$0.04(-9.27%)
At close: 4:00 PM EST
$0.54
-$0.04(-9.27%)
Day’s Range― - ―
52-Week Range$0.35 - $5.84
Previous CloseN/A
Volume845.14K
Average Volume (3M)255.21K
Market Cap
$4.71M
Enterprise Value$14.32M
Total Cash (Recent Filing)$17.85M
Total Debt (Recent Filing)$24.82M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Jun 29, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.42
Shares Outstanding12,692,684
10 Day Avg. Volume196,512
30 Day Avg. Volume255,205
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.36
Price to Sales (P/S)4.98
P/FCF Ratio-0.42
Enterprise Value/Market Cap3.04
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit113.67
Enterprise Value/Ebitda-0.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$12.75M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross Profit TurnaroundSustained double‑digit revenue growth with a shift to positive gross profit signals improving unit economics. If growth and margin gains persist, scaling revenues can absorb fixed costs, narrow operating losses and materially strengthen the path to durable profitability over 2–6 months.
Commercial Traction And Recurring Revenue ChannelsHigh customer retention, multiyear contracts and GPO coverage create recurring consumable demand and predictable revenue streams. Broad international distribution diversifies adoption and shortens marginal sales cycles for repeat accessory sales, strengthening long‑term revenue durability.
Gen II Product Progress With Material Margin UpsideA smaller, more service‑efficient Gen II device can expand addressable markets while lowering service and unit costs. Achieving longer service intervals and higher gross margins would structurally improve profitability per unit and create a sustainable competitive advantage if regulatory timing aligns.
Bears Say
Large And Persistent Cash BurnHeavy negative operating and free cash flow relative to a small revenue base creates ongoing funding needs. Continued cash burn increases dilution and refinancing risk, constraining the company’s ability to invest in commercial scale, R&D or cushion against execution delays over the medium term.
Elevated Leverage And Weakened Equity CushionRising debt alongside falling equity reduces financial flexibility and increases solvency risk. With limited equity cushion, adverse revenue or cash‑flow shocks could force dilutive financings or restrictive debt terms, limiting strategic optionality and raising long‑term cost of capital.
Nasdaq Listing Noncompliance And Potential DelistingListing noncompliance and the prospect of delisting materially raise liquidity and capital‑access risks. A delisting or prolonged uncertainty can shrink the investor base, increase financing costs and impair recruitment/partner confidence, creating a durable headwind for execution over coming months.
Beyond Air News
XAIR FAQ
What was Beyond Air’s price range in the past 12 months?
Beyond Air lowest stock price was $0.35 and its highest was $5.84 in the past 12 months.
What is Beyond Air’s market cap?
Beyond Air’s market cap is $4.71M.
When is Beyond Air’s upcoming earnings report date?
Beyond Air’s upcoming earnings report date is Jun 29, 2026 which is in 12 days.
How were Beyond Air’s earnings last quarter?
Beyond Air released its earnings results on Feb 13, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.75 by -$0.1.
Is Beyond Air overvalued?
According to Wall Street analysts Beyond Air’s price is currently Overvalued.
Does Beyond Air pay dividends?
Beyond Air does not currently pay dividends.
What is Beyond Air’s EPS estimate?
Beyond Air’s EPS estimate is -0.57.
How many shares outstanding does Beyond Air have?
Beyond Air has 12,692,684 shares outstanding.
What happened to Beyond Air’s price movement after its last earnings report?
Beyond Air reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.75. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Beyond Air?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational momentum: double‑digit sequential growth, a 105% year‑over‑year revenue increase, a gross profit turnaround, significant cuts to operating costs (36% YoY) and extended commercial reach (45+ hospitals, VA sale, GPO coverage and 40-country distribution). Management secured additional capital and a pending NeuroNOS transaction that could de‑risk noncore R&D and create upside. Primary risks discussed were continued unprofitability and cash burn despite improvement, low absolute revenue and current gross margins, dependence on a contract manufacturer inspection and FDA timing for Gen II, lengthy sales cycles, and pending/contingent aspects of financing and the NeuroNOS sale. On balance the positive operational and financial momentum and progress toward Gen II and commercialization outweighed the remaining challenges.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
71.49% Insiders
1.77% Mutual Funds
4.87% Other Institutional Investors
21.62% Public Companies and
Individual Investors